Atopic dermatitis
Atopic dermatitis is a chronic condition that causes skin inflammation, redness, and irritation. It commonly begins in childhood, though it can develop at any age. The condition is not contagious and cannot be passed from person to person. Atopic dermatitis typically causes intense itching, and scratching can worsen the skin, leading to increased redness, swelling, cracking, oozing of clear fluid, crusting, and scaling. The disease often alternates between flare-ups, when symptoms are more severe, and periods of remission, during which the skin may improve or clear completely.
Symptoms:
The primary symptom of atopic dermatitis is intense itching, which can be severe.
Other common symptoms include:
• Red, dry patches of skin
• Rashes that may ooze, leak clear fluid, or bleed when scratched
• Thickening and hardening of the skin
Drug Class Distribution and Development Phases
According to the AdisInsight database, the following is a comprehensive overview of drugs grouped into eleven main drug classes, along with their respective development phases.
Table 17- Drug Distribution Breakdown for Atopic Dermatitis
The graph clearly illustrates that small molecules are dominating the development phase, with forty-six drugs in early-stage clinical development and five drugs in late-stage clinical development.
Drug development phases Vs drug class
Fig 4: Development phases of drugs versus drug class distribution
Analysis of Development Phases and Routes of Administration
According to the AdisInsight database, the following graph shows that the subcutaneous route of administration is the most common for treating Atopic Dermatitis, with thirty-nine drugs in earlystage clinical development, eleven in late-stage clinical development, and two in the registered phase.
Drug development phases Vs RoA
Fig 5: Development phases of drugs versus RoA distribution
Overview of Development Stages and Formulations
Based on the AdisInsight database, injection formulations are leading the development stages, with twenty-nine drugs in early-stage clinical development, eleven in late-stage clinical development, and two in the registered phase.
Drug development phases Vs formulation of drugs
Fig 6: Development phases of drugs versus formulation
Drugs Available for Licensing
Licensing information for atopic dermatitis drugs is crucial as it directly impacts market expansion and profit potential. For example, Dupixent (dupilumab), acquired by Sanofi from Regeneron Pharmaceuticals for the treatment of atopic dermatitis, generated $8.7 billion in sales in 2022, marking a 40% increase compared to 2021. According to the AdisInsight database, the following drugs are currently available for licensing: thirteen in early-stage clinical development, one in latestage clinical development, and fifteen in the preclinical or research phase.
Table 18- Drugs available for licensing for Atopic dermatitis